Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.

ABSTRACT:

Background

Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone.

Methods

The Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF) trial randomized 360 acute HF patients with reduced or preserved ejection fraction to spironolactone 100 mg daily or usual care for 96 hours. The current analysis assessed the effects of study therapy within tertiles of baseline estimated glomerular filtration rate (eGFR) and subgroups at heightened risk for diuretic resistance.

Results

Across eGFR tertiles, there was no incremental benefit of high-dose spironolactone on any efficacy endpoint, inclu

SUBMITTER: Greene SJ 

PROVIDER: S-EPMC6685766 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature